CALCITONIN AND BISPHOSPHONATES TREATMENT IN BONE LOSS AFTER LIVER-TRANSPLANTATION

被引：92

作者：

VALERO, MA

LOINAZ, C

LARRODERA, L

LEON, M

MORENO, E

HAWKINS, F

机构：

[1] UNIV HOSP MADRID,SERV ENDOCRINOL,E-28041 MADRID,SPAIN

[2] UNIV HOSP MADRID,DEPT SURG,MADRID,SPAIN

[3] UNIV HOSP MADRID,SERV BIOCHEM,MADRID,SPAIN

来源：

CALCIFIED TISSUE INTERNATIONAL | 1995年 / 57卷 / 01期

关键词：

D O I：

10.1007/BF00298990

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Osteopenia is a major complication of orthotopic liver transplantation (OLT). However, no effective therapy for bone disease has been defined. We have studied vertebral bone mineral density (VMD) and fasting serum markers of bone formation [bone gla protein (BGP), procollagen I carboxyterminal peptide (PICP)] and metabolism (serum Ca, P, intact parathyroid hormone (iPTH), 25OHD(3) and 1,25(OH)(2)D-3) in 120 patents after OLT. VMD was measured by dual-energy X-ray absorptiometry (DXA) using a Hologic QDR 1000 densitometer on two occasions, 12 months apart. Patients with OLT had a VBD significantly lower compared with age- and sexed-matched Spanish controls (P < 0.05). Prevalence of osteoporosis (Z score below -2 SD) was 35.8%. Serum BGP (8.6 +/- 0.7 ng/ml) and PICP (222.9 +/- 81.9 ng/dl) were higher than those of controls. However, serum calcium, phosphorus, iPTH, 25OHD(3), and 1,25(OH)2D(3) were within normal range. Patients with osteoporosis were randomly treated with 40 IU/day of calcitonin i.m. (Diatin, Ferrer Int. Laboratories) (n = 17) or 400 mg p.o., 15 days every 3 months, of sodium ethiodronate (Difosfen, Rubio Laboratories) (n = 23). All patients received 500 mg/12 hours of elemental calcium p.o. After 12 months of treatment, a significant increment of vertebral mineral density (VMD) was observed (6.4% and 8.2%, respectively). Serum BGP and PICP values remained elevated without a difference between the two drugs. Our results indicate that antiresorptive drugs may be of benefit in the high turnover osteoporosis of OLT recipients.

引用

页码：15 / 19

页数：5

共 29 条

[1] Eastell R., Dickson R., Hodgson S.F., Wiesner R.H., Porayko M.K., Wahner H.W., Et al., Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis, Hepatology, 14, pp. 296-300, (1991)
[2] Porayko M.K., Wiesner R.H., Hay J.E., Krom R.A.F., Dickson E.R., Beaver S., Et al., Bone disease in liver transplant recipients: incidence, timing and risk factors, Trans Proc, 23, pp. 1462-1465, (1991)
[3] McDonall J.A., Dunstan C.R., Dilworth P., Sherbon K., Sheil A.G., Evans R.A., Et al., Bone loss after liver transplantation, Hepatology, 14, pp. 613-619, (1991)
[4] Hawkins F.G., Leon M., Lopez M.B., Valero M.A., Larrodera L., Garcia I., Et al., Bone loss and turnover in patients with liver transplantation, Hepato-Gastroenterol, 41, pp. 158-161, (1994)
[5] Diamond T.H., Stiel D., Lunzer H., McDowall D., Eckstein R.P., Posen S., Hepatic osteodystrophy: static and dynamic bone histomorphometry and serum bone Gla-protein in 80 patients with chronic liver disease, Gastroenterology, 96, pp. 213-221, (1989)
[6] Saitta J.C., Ott S.M., Sherrard D.J., Walden C.E., Lipkin E.W., Metabolic bone disease in adults receiving long-term parenteral nutrition: longitudinal study with regional densitometry and bone biopsy, JPEN, 17, pp. 214-219, (1993)
[7] Stewart A.F., Adler M., Byers C.M., Segre G.V., Broadus A.E., Calcium homeostasis in immobilization: an example of resorptive hypercalciuria, N Engl J Med, 306, pp. 1136-1140, (1982)
[8] Lukert B.P., Raisz L.G., Glucocorticoid-induced osteoporosis: pathogenesis and management, Ann Intern Med, 112, pp. 355-364, (1990)
[9] Stewart P.J., Stern P.H., Cyclosporine: correlation of immunosuppressive activity and inhibition of bone resorption, Calcif Tissue Int, 45, pp. 222-226, (1989)
[10] Moskowitz C., Epstein S., Fallon M., Ismail F., Thomas S., Cyclosporin-A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration, Endocrinology, 123, pp. 2571-2577, (1988)

← 1 2 3 →